Please login to the form below

Not currently logged in
Email:
Password:

Mirna Therapeutics appoints new executive vice president

Miguel Barbosa willalso serve as chief scientific officer

Mirna Therapeutics has appointed Dr Miguel Barbosa as executive vice president and chief scientific officer.

Mirna Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics.

Barbosa joined the company with 20 years of biopharmaceutical research discovery experience and for the past decade has served in senior leadership roles at Johnson & Johnson subsidiaries.

Paul Lammers, Mirna's president and chief executive officer, said: “We are pleased to welcome Miguel to the role of chief scientific officer.

As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel's expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”

30th October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics